Device Trial Radar · NCT04750889
Breast Localization: RFID Tags vs Wire Localization
Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
May 15, 2021
Primary completion
Apr 24, 2023
Study completion Apr 24, 2023
Sponsor
- Lead sponsor
- Centre Jean PerrinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 11, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device compared to the gold standard device.
Conditions
- Breast Neoplasm Female
Interventions
RFID tagsDevice
Installation of the RFID tag device wire localization)
Wire localizationDevice
Installation of the wire localization device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the patients satisfactionTime frame: 1 years and 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Jean PERRIN
Clermont-Ferrand, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.